-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Palonosetron as an anti-emetic and anti-nausea agent in oncology
(2395) Views (654) Full article downloads
Authors: Matti S Aapro
Published Date January 2007
Volume 2007:3(6) Pages 1009 - 1020
DOI: http://dx.doi.org/10.2147/TCRM.S
Matti S Aapro
Clinique de Genolier, Genolier, Switzerland
Abstract: Palonosetron (Aloxi®, Onicit®, Paloxi®) is a second-generation 5-HT3 receptor antagonist (RA) with an extended half-life of ~40 hours and high binding affi nity for the 5-HT3 receptor that is markedly different from other 5-HT3 RAs. Phase III trials demonstrate that a single dose of palonosetron compared with traditional 5-HT3 RAs is more effective in preventing chemotherapy-induced nausea and vomiting (CINV) during the first 24 hours following chemotherapy (acute CINV), and also exhibits prolonged efficacy to provide significantly better protection from CINV in the delayed and overall phases. This superior and extended protection from CINV conferred by palonosetron following a single intravenous dose before chemotherapy simplifies dosing schedules. Recent research has focused on optimization of palonosetron-based antiemetic regimens, particularly in combination with steroids and neurokinin-1 RAs. The available clinical data indicate high control rates for palonosetron, suggesting a synergistic potential for protection in patients scheduled to receive emetogenic drug regimens.
Keywords: palonosetron, CINV, 5-HT3 receptor antagonists, moderately emetogenic chemotherapy (MEC), highly emetogenic chemotherapy (HEC)
Readers of this article also read:
Prolonged rupture of membranes in term infants: should all babies be screened?
Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects
Health literacy and health seeking behavior among older men in a middle-income nation
ABO and rhesus blood group distribution in Kurds
Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision
Management of traumatic events: influence of emotion-centered coping strategies on the occurrence of dissociation and post-traumatic stress disorder
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




